Lenalidomide cap. 25mg Sobhan Oncology (LENASOB® 25mg), In-Vivo Bioequivalence in iranian healthy volunteer.

In- Vivo Bioequivalence study of Lenalidomide cap. 25mg Sobhan Oncology (LENASOB® 25mg) with brand drug (REVLIMID® 25mg Colgene, Bristol-Myers Squibb) in Iranian healthy volunteers

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200105046010N26

Enrollment

Registered

2021-03-12

Start date

2021-03-15

Completion date

Unknown

Last updated

2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

In this study, the disease is not examined. Subject bioequivalence test and reference tablets Teriflunomide studied..

Interventions

Intervention 1: Intervention group: Intervention group received one test drug table(Lenalidomide cap. 25mg Sobhan Oncology Pharma). Blood samples were taken from the volunteers for 72 hours at the men

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: General health(liver, heart, kidney) Body mass index(18-28) Informed consent Age(18-60)

Exclusion criteria

Exclusion criteria: Smoking A history of cardiovascular disease A history of liver & kidney disease Pregnancy Alcohol & Drug addiction Hypersensitivity to the drug

Design outcomes

Primary

Measure	Time frame
Determination of blood drug concentration. Timepoint: Sampling times in this study will be 0, 1, 2, 2:30, 3, 3:20, 3:40, 4, 4:20, 4: 40, 5, 6, 8, 10, 12, 24, 48, 72 hours After prescribing the tablet. Method of measurement: igh Performance Liquid Chromatography with tandem mass spectroscopy detector.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactJavad Shokri

Tabriz University of Medical Sciences

Shokri.j@gmail.com+98 41 3334 8489

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026